{"prompt": "['CONFIDENTIAL', 'Protocol 235-9051-202 - Amendment 1', 'For VIIS and I-NRS, the treatment groups will be compared with respect to the change from Baseline using', 'mixed model of repeated measures (MMRM) including terms for treatment, visit, treatment by visit', 'interaction, and the Baseline value serving as the covariate. From the model, the active to vehicle treatment', 'differences will be estimated. Additionally, two-sided confidence intervals will be provided.', 'Handling of missing data: Data summaries and analyses will use observed data only without imputation', 'of missing values. Supplementary analysis will be performed to investigate the impact of data imputation', 'on the primary endpoint as follows:', '1) by assuming that subjects with missing data are treatment successes (\"best case\"); and', '2) by assuming that subjects in the vehicle group with missing data are \"treatment success\" and that subjects', 'in the TMB-001 groups with missing data are treatment failures (\"worst case\").', '3) by assuming that subjects with missing data maintain their last observed rating from which treatment', 'success or failure will be derived at Visit 6 (\"LOCF\").', 'Dosing Compliance', 'Descriptive statistics will be used to summarize study treatment compliance for the ITT population. A', 'subject will be considered compliant with the dosing regimen if the subject applies at least 80% but no more', 'than 120% of the expected number of applications or dose.', 'Safety Analyses:', 'The safety analyses will be conducted on the Safety population.', 'Extent of Exposure', 'The total amount of study medication used (grams of study medication applied) will be calculated from the', 'weights of the returned study medication tubes. Descriptive statistics (mean, median, SD, minimum and', 'maximum) will be determined for the total amount of study medication used by each subject by treatment', 'groups.', 'Physical Examinations', 'Findings from physical examinations (head and neck, cardiovascular, dermatological, respiratory,', 'gastrointestinal [abdomen], and gross motor and gait) will be recorded in medical history (from assessment', 'at Visit 1 [Screening] and Visit 2 [Baseline])', 'Vital Signs', 'Descriptive statistics of vital signs (temperature, systolic and diastolic blood pressure, heart rate, and', 'respiration rate) at Visit 1 (Screening) and Visit 6 (EOS) will be provided by treatment group.', 'Clinical Laboratory Tests', 'Clinical laboratory tests will be evaluated for any material changes during the study period. All laboratory', 'data (hematology, chemistry, and urinalysis) will be listed and reported in the units received by the', 'laboratory. Shift tables by analyte and by out of range flag will be presented to facilitate the evaluation of', 'change from Visit 1 (Screening) to Visit 6 (EOS).', 'Urine Pregnancy Test', 'Urine pregnancy test (UPT) results (if applicable) from Visit 2 (Baseline), Visit 4, Visit 5, and Visit 6 (EOS)', 'will be provided in a listing.', 'Local Skin Reactions', 'Local skin reactions (LSRs) (including burning/stinging, erythema, erosions, and edema) will be', 'summarized by frequency of each individual LSR for each treatment group. Change from Baseline in LSRs', \"will be categorized into 'worsened' and 'same or improved' and will be tabulated.\", '11']['CONFIDENTIAL', 'Protocol 235-9051-202 - Amendment 1', 'Adverse Events', 'All AEs reported during the study will be listed, documenting onset, whether therapy was required, any', 'change in study treatment dosing, severity, possible relationship to study treatment, and outcome. Verbatim', 'terms on the case report forms (CRFs) will be linked to preferred terms (PTs) and system organ class (SOC)', 'using the Medical Dictionary for Regulatory Activities (MedDRA) mapping system. All reported AEs will', 'be summarized by the number of subjects reporting AEs, SOC, PT, severity, and relationship to study', 'treatment by treatment group.', 'Data Monitoring Committee: No', '12']\n\n###\n\n", "completion": "END"}